BACKGROUND: Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m2 and irinotecan 50 mg/m2 given on days 1 and 8 of a 21-day schedule. MATERIALS AND METHODS: Patients who had unresectable/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, measurable disease, Eastern Cooperative Oncology Group performance status of zero to two, and normal bilirubin were eligible. Tumor assessment was carried out every three cycles. RESULTS: We enrolled 29 chemotherapy-naive (CN) and 15 chemotherapy-exposed (CE) eligible patients. Principal toxic effects were diarrhea, neutropenia, and hyperglycemia. There were no toxic deaths. There was one early death, from myocardial infarction. Among 26 CN and assessable patients, there were seven (26.9%) with a partial response (PR) and one (3.8%) with a complete response (CR). There were two PRs and one CR among the patients with CE disease. Median time to progression for CN patients was 4.0 months and for CE patients 3.5 months. Median survival for CN eligible patients was 9.0 months and for CE patients 11.4 months. CONCLUSIONS: Docetaxel-irinotecan combination given on a weekly x 2 of 3 schedule is promising in the treatment of advanced esophageal cancer.
BACKGROUND: Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m2 and irinotecan 50 mg/m2 given on days 1 and 8 of a 21-day schedule. MATERIALS AND METHODS:Patients who had unresectable/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, measurable disease, Eastern Cooperative Oncology Group performance status of zero to two, and normal bilirubin were eligible. Tumor assessment was carried out every three cycles. RESULTS: We enrolled 29 chemotherapy-naive (CN) and 15 chemotherapy-exposed (CE) eligible patients. Principal toxic effects were diarrhea, neutropenia, and hyperglycemia. There were no toxic deaths. There was one early death, from myocardial infarction. Among 26 CN and assessable patients, there were seven (26.9%) with a partial response (PR) and one (3.8%) with a complete response (CR). There were two PRs and one CR among the patients with CE disease. Median time to progression for CN patients was 4.0 months and for CE patients 3.5 months. Median survival for CN eligible patients was 9.0 months and for CE patients 11.4 months. CONCLUSIONS:Docetaxel-irinotecan combination given on a weekly x 2 of 3 schedule is promising in the treatment of advanced esophageal cancer.
Authors: A A Adjei; C E Klein; H Kastrissios; R M Goldberg; S R Alberts; H C Pitot; J A Sloan; J M Reid; L J Hanson; P Atherton; J Rubin; C Erlichman Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: C Couteau; M L Risse; M Ducreux; F Lefresne-Soulas; A Riva; A Lebecq; P Ruffié; P Rougier; F Lokiec; R Bruno; J P Armand Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: Eric Bleickardt; Athanassios Argiris; Randy Rich; Kathi Blum; Anne McKeon; Harold Tara; Daniel Zelterman; Barbara Burtness; Marianne J Davies; John R Murren Journal: Cancer Biol Ther Date: 2002 Nov-Dec Impact factor: 4.742
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: M Dank; J Zaluski; C Barone; V Valvere; S Yalcin; C Peschel; M Wenczl; E Goker; L Cisar; K Wang; R Bugat Journal: Ann Oncol Date: 2008-06-16 Impact factor: 32.976
Authors: J Matsubara; T Nishina; Y Yamada; T Moriwaki; T Shimoda; T Kajiwara; T E Nakajima; K Kato; T Hamaguchi; Y Shimada; Y Okayama; T Oka; K Shirao Journal: Br J Cancer Date: 2008-01-29 Impact factor: 7.640
Authors: J Wei; Z Zou; X Qian; Y Ding; L Xie; J J Sanchez; Y Zhao; J Feng; Y Ling; Y Liu; L Yu; R Rosell; B Liu Journal: Br J Cancer Date: 2008-03-25 Impact factor: 7.640
Authors: Bo Zhang; Xi Wang; Qun Li; Hongnan Mo; Xingyuan Wang; Yan Song; Jianping Xu; Tao Qu; Jing Huang Journal: Chin J Cancer Res Date: 2019-12 Impact factor: 5.087